Contrasting Capstone Therapeutics (CAPS) and Its Peers

Capstone Therapeutics (NASDAQ:CAPS) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its rivals? We will compare Capstone Therapeutics to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.

Institutional & Insider Ownership

2.5% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 59.1% of Capstone Therapeutics shares are held by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Capstone Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	N/A	N/A	N/A
Capstone Therapeutics Competitors	-1,425.99%	-589.65%	-28.81%

Analyst Ratings

This is a summary of current recommendations and price targets for Capstone Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1	0	0	0	1.00
Capstone Therapeutics Competitors	5770	12187	37606	1167	2.60

As a group, “MED – BIOMED/GENE” companies have a potential upside of 55.16%. Given Capstone Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Capstone Therapeutics has less favorable growth aspects than its rivals.

Volatility & Risk

Capstone Therapeutics has a beta of -0.83, meaning that its stock price is 183% less volatile than the S&P 500. Comparatively, Capstone Therapeutics’ rivals have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Earnings & Valuation

This table compares Capstone Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Capstone Therapeutics	$43.38 million	-$2.56 million	-1.25
Capstone Therapeutics Competitors	$953.83 million	-$45.25 million	12.33

Capstone Therapeutics’ rivals have higher revenue, but lower earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Capstone Therapeutics rivals beat Capstone Therapeutics on 8 of the 13 factors compared.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.